1
|
Ma X, Xia K, Xie J, Yan B, Han X, Li S, Wang Y, Fu T. Treatment of Idiopathic Pulmonary Fibrosis by Inhaled Silybin Dry Powder Prepared via the Nanosuspension Spray Drying Technology. ACS Pharmacol Transl Sci 2023; 6:878-891. [PMID: 37325446 PMCID: PMC10262316 DOI: 10.1021/acsptsci.3c00033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2023] [Indexed: 06/17/2023]
Abstract
Idiopathic pulmonary fibrosis (IPF) is a kind of life-threatening interstitial lung disease characterized by progressive dyspnea with accurate pathogenesis unknown. At present, heat shock protein inhibitors are gradually used to treat IPF. Silybin, a heat shock protein C-terminal inhibitor, has high safety and good application prospects. In this work, we have developed a silybin powder able to be used for inhalation administration for the treatment of IPF. Silybin powder was prepared by the spray drying method and identified using cascade impactometry, particle size, scanning electron microscopy (SEM), differential scanning calorimetry (DSC), X-ray diffraction (XRD), and Fourier transform infrared (FT-IR) spectroscopy. A rat model of bleomycin-induced IPF was used to assess the effect of inhaled silybin spray-dried powder. Lung hydroxyproline content, wet weight, histology, inflammatory factor expression, and gene expression were examined. The results showed that inhaled silybin spray-dried powder alleviated inflammation and fibrosis, limited hydroxyproline accumulation in the lungs, modulated gene expression in the development of IPF, and improved postoperative survival. The results of this study suggest that silybin spray-dried powder is an attractive candidate for the treatment of IPF.
Collapse
|
2
|
Eedara BB, Bastola R, Das SC. Dissolution and Absorption of Inhaled Drug Particles in the Lungs. Pharmaceutics 2022; 14. [PMID: 36559160 DOI: 10.3390/pharmaceutics14122667] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2022] [Revised: 11/15/2022] [Accepted: 11/25/2022] [Indexed: 12/02/2022] Open
Abstract
Dry powder inhalation therapy has been effective in treating localized lung diseases such asthma, chronic obstructive pulmonary diseases (COPD), cystic fibrosis and lung infections. In vitro characterization of dry powder formulations includes the determination of physicochemical nature and aerosol performance of powder particles. The relationship between particle properties (size, shape, surface morphology, porosity, solid state nature, and surface hydrophobicity) and aerosol performance of an inhalable dry powder formulation has been well established. However, unlike oral formulations, there is no standard dissolution method for evaluating the dissolution behavior of the inhalable dry powder particles in the lungs. This review focuses on various dissolution systems and absorption models, which have been developed to evaluate dry powder formulations. It covers a summary of airway epithelium, hurdles to developing an in vitro dissolution method for the inhaled dry powder particles, fine particle dose collection methods, various in vitro dissolution testing methods developed for dry powder particles, and models commonly used to study absorption of inhaled drug.
Collapse
|
3
|
Hastedt JE, Bäckman P, Cabal A, Clark A, Ehrhardt C, Forbes B, Hickey AJ, Hochhaus G, Jiang W, Kassinos S, Kuehl PJ, Prime D, Son YJ, Teague S, Tehler U, Wylie J. iBCS: 1. Principles and Framework of an Inhalation-Based Biopharmaceutics Classification System. Mol Pharm 2022; 19:2032-2039. [PMID: 35576168 PMCID: PMC9257742 DOI: 10.1021/acs.molpharmaceut.2c00113] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
![]()
For oral drugs, the
formulator and discovery chemist have a tool
available to them that can be used to navigate the risks associated
with the selection and development of immediate release oral drugs
and drug products. This tool is the biopharmaceutics classification
system (giBCS). Unfortunately, no such classification system exists
for inhaled drugs. The perspective outlined in this manuscript provides
the foundational principles and framework for a classification system
for inhaled drugs. The proposed classification system, an inhalation-based
biopharmaceutics classification system (iBCS), is based on fundamental
biopharmaceutics principles adapted to an inhalation route of administration
framework. It is envisioned that a classification system for orally
inhaled drugs will facilitate an understanding of the technical challenges
associated with the development of new chemical entities and their
associated new drug products (device and drug formulation combinations).
Similar to the giBCS, the iBCS will be based on key attributes describing
the drug substance (solubility and permeability) and the drug product
(dose and dissolution). This manuscript provides the foundational
aspects of an iBCS, including the proposed scientific principles and
framework upon which such a system can be developed.
Collapse
Affiliation(s)
- Jayne E Hastedt
- JDP Pharma Consulting, San Carlos, California 94070, United States
| | | | - Antonio Cabal
- Eisai, Woodcliff Lake, New Jersey 07677, United States
| | - Andy Clark
- Aerogen Pharma, San Mateo, California 94402, United States
| | | | - Ben Forbes
- King's College London, London WC2R 2LS, United Kingdom
| | - Anthony J Hickey
- University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States
| | | | - Wenlei Jiang
- U.S. FDA, Center for Drug Evaluation and Research, Office of Generic Drugs, Office of Research and Standards, Silver Spring, Maryland 20993, United States
| | | | - Philip J Kuehl
- Lovelace Biomedical, Albuquerque, New Mexico 87108, United States
| | - David Prime
- Pulmonary Drug Delivery Consultant, Ware SG12, United Kingdom
| | - Yoen-Ju Son
- Genentech, South San Francisco, California 94080, United States
| | - Simon Teague
- GlaxoSmithKline, Stevenage SG1 2NY, United Kingdom
| | - Ulrika Tehler
- Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg 43183, Sweden
| | | |
Collapse
|